• Mylan Pharmaceuticals Inc., of Pittsburgh, settled a dispute with Teva Pharmaceuticals USA Inc., part of Teva Pharmaceutical Industries Ltd., of Jerusalem, over litigation brought by Mylan against the FDA related to Mylan's abbreviated new drug application for Modafinil tablets, 100 mg and 200 mg. The product is a generic version of Provigil, by Cephalon Inc., of Frazer, Pa. The agreement with Teva stipulates that Mylan may launch its Modafinil tablets on Aug. 10, prior to the expiration of the 180-day marketing exclusivity period granted to Teva.